OncoSec Medical Incorporated (ONCS)
-OTC Markets 0.27 Jun 18, 3:59PM EDT|Pre-Market
:
NaN
| Prev Close: | 0.27 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | -25.88 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.17 - 0.49 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,414,570 |
|---|
| Market Cap: | 31.39M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OncoSec Medical Announces Completion of Enrollment of Phase II Metastatic Melanoma TrialBusiness Wire(Tue, Jun 18)
- [$$] Can Green Mountain Coffee and 4 Biotechs Climb?at Barrons.com(Mon, Jun 17)
- Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughsat Minyanville(Mon, Jun 17)
- ONCOSEC MEDICAL INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, Jun 14)
- OncoSec's And Ziopharm's IL-12 Targeted Delivery Systems: Which Will Succeed?at Seeking Alpha(Wed, Jun 12)
- OncoSec signs SRA woth Old Dominion University and Frank Reidy Research Centerat theflyonthewall.com(Tue, Jun 11)
- OncoSec Medical Enters Sponsored Research Agreement with Old Dominion University for Combination Study in MelanomaBusiness Wire(Tue, Jun 11)
- ONCOSEC MEDICAL INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Thu, Jun 6)
- OncoSec Medical to Present at the Second Annual Marcum LLP MicroCap ConferenceBusiness Wire(Tue, May 21)
- 3 Small Cap Cancer Stocks With Upcoming Catalystsat Seeking Alpha(Mon, May 20)
- A Comprehensive Overview Of Active Electroporation Cancer Trialsat Seeking Alpha(Tue, May 14)
- OncoSec Medical Incorporated President and CEO Publishes New Blog Entitled ''Why Electroporation?''Accesswire(Fri, May 10)
- OncoSec Medical to Present at the Sachs Cancer Bio Partnering Forum and Participate in a Panel Discussion on Immunotherapies and Cancer VaccinesBusiness Wire(Tue, May 7)
- Companies Developing Targeted Cancer Treatments Seek Higher Profits In 2013at Seeking Alpha(Mon, May 6)
- Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trialat Seeking Alpha(Fri, May 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jul-13)
: | N/A |
|---|
| Quarterly EPS Est
(Oct-12)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
OncoSec Medical Incorporated designs, develops, and commercializes novel cancer therapeutic products in the United States. Its products combine proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherap...
View More 
0.91%